OSX
Director Trades
| Date | Director | Value |
|---|
Company News
Osteopore Granted Swiss Market Approval for Custom Bioresorbable Implants
Regenerative medicine company Osteopore (ASX: OSX) has secured market approval in Switzerland for its off-the-shelf and custom-made biomimetic and bioresorbable implants. Approval came under the European Union’s medical device regulations (MDR) and follows the company’s partnership with US orthopaedic solutions company Zimmer Biomet to distribute its craniofacial products in Europe, the Middle East and Africa, the […]
Osteopore granted European market approval for custom orthopaedic and cranial implants
Regenerative medicine company Osteopore (ASX: OSX) has secured European Union medical device regulation approval for its custom orthopaedic and cranial implants. The approval unlocks opportunities for the company to offer high-value custom implants to the European market to complement its range of off-the-shelf neurosurgical and craniofacial implants. Osteopore will distribute the products via an exclusive […]
Osteopore granted regulatory approval for innovative bone reconstruction procedures in Singapore and Vietnam
Regenerative medicine specialist Osteopore (ASX: OSX) is set to help relieve the knee pain of thousands of sufferers with the company now able to use several of its procedures in Singapore and Vietnam. In a milestone for Osteopore’s growth strategy, the company’s aXOpore technology has been granted regulatory clearance by Singapore’s Health Sciences Authority and […]
Osteopore and Singular Health collaborate on AI-powered cranial implant design process
Bone healing biotech Osteopore (ASX: OSX) has inked a deal with Singular Health Group (ASX: SHG) for a comparative study between Osteopore’s existing cranial implant design process and a new artificial intelligence design engine in a clinical environment. The study seeks to validate the results of the new AI engine, using Osteopore’s data set of […]
Osteopore’s regenerative bone implants to be further developed under new clinical trials
Osteopore (ASX: OSX) will further refine its next generation scaffolds after agreeing to sponsor two clinical trials for its regenerative implants in Australia. Under a new agreement, world recognised Queensland-based plastic and reconstructive surgeon Dr Michael Wagels will lead two human clinical trials that will run up to five years. The trial will use Osteopore’s […]
Osteopore improves margins ahead of forecast increase in elective surgeries
Medical technology company Osteopore (ASX: OSX) says the “robust capital position” it ended the June quarter in will enable it to take advantage of an expected increase in elective surgeries. The Australian and Singapore-based company, which has commercialised a range of patented 3D printed bioresorbable scaffolds for bone regeneration, recorded S$308,865 (A$301,237) in revenue and […]
Osteopore receives European certification for expanded line of bone healing products
Australian-Singaporean medical technology company Osteopore (ASX: OSX) has received European CE Mark certification for seven new designs in its range of 3D-printed biomimetic, bioresorbable craniofacial scaffold products for regenerative bone healing. The company now has a total of 10 shape and size variants relating to Osteomesh, Osteoplug and Osteoplug-C surgical products and has extended their […]
Osteopore collars European patent for next generation bone regenerative implant technology
Osteopore’s (ASX: OSX) bone healing technology has reached another milestone after the European Patent Office granted a patent for the company’s next generation of regenerative implants. The patent EP 3218019 A4 covers Osteopore’s process which involves combining a soluble magnesium salt filler with a suitable polymer to produce “smart” 3D biomimetic scaffolds without solvents or […]
Osteopore reports consistent revenue growth and upscales global distribution
Osteopore (ASX: OSX) has updated the market with strong company performance figures, declaring it recorded four straight quarters of revenue growth last year including a $429,700 result in the 2020 fourth quarter. Despite the emergence of COVID-19 in 2020, Osteopore reported continued sales growth throughout the year, and in the fourth quarter, a 5% increase compared […]
Osteopore signs deal to distribute medical implant products through German and Austrian markets
Bone healing biotech Osteopore (ASX: OSX) has signed an exclusive two-year agreement with medical device distributor MTG Medizintechnik Göhl to promote and sell its products in Germany and Austria. Under the terms of the agreement, MTG will market Osteopore’s range of products for craniofacial procedures, as well as patient-specific implants. The company’s Osteoplug, Osteoplug-C and […]
